GSK continues to stock up on Wave's RNA drugs with liver-focused program
GSK is paying Wave Life Sciences $12 million upfront for a liver-focused RNA drug program. The deal includes potential milestone payments of up to $375 million and royalties. GSK has selected four programs from their 2022 collaboration, with three more under review. Wave's CEO highlighted the company's differentiated technology and ongoing collaboration.
How this was made
The 30-second read
Why it matters
The partnership underscores GSK's strategy to diversify into RNA therapeutics, while Wave gains funding and potential royalties.
Market read
New GSK‑Wave deal adds to RNA sector activity; modest immediate price impact expected.
What to watch
Potential future milestones up to $375 M could materially benefit GSK if the program succeeds.
Background
GSK expands its RNA therapeutic pipeline by acquiring a liver‑focused siRNA candidate from Wave Life Sciences.
Ticker impact
GSK paid $12 million upfront to Wave Life Sciences for a new hepatic siRNA program.
likely slight pressure as the market prices the $12 M payment, with upside potential if milestones are met
The deal is a new primary disclosure; the upfront amount is modest for GSK, so impact is limited.
Market effects
Highlights continued interest in RNA therapeutics, may boost sector sentiment for other RNA companies.
UK‑based Wave gains visibility, but no immediate market effect.
Limited to biotech investors tracking RNA platform collaborations.
Counterpoint
The modest upfront payment suggests limited upside; investors may view the deal as a cash drain.
Key entities
- companyGSK
Global pharmaceutical company acquiring the program.
- companyWave Life Sciences
Private RNA therapeutics developer partnering with GSK.
